CurrentUnitedHealthcarePolicy 2025D0121P

Provider Administered Drugs - Site of Care

Defines clinical criteria and documentation required to allow outpatient hospital facility infusion (place of service 19 or 22) for specialty medications and IVIG/SCIG; applies to providers submitting requests for facility-based infusion services under UnitedHealthcare Commercial plans.

Policy Summary

PayerUnitedHealthcare

PolicyProvider Administered Drugs - Site of Care

Policy CodePolicy 2025D0121P

Change TypeOperational updates to coding and supporting content (non-material)

Effective Date07/01/2025

Next Review DateN/A

Key ActionSubmit medical records and obtain prior authorization when requesting outpatient hospital facility infusion (place of service 19 or 22) to document medical necessity.

SourceLink

POLICY UPDATE CHANGES

Updated list of applicable HCPCS codes to reflect quarterly edits; revised description for Q9998

Updated Benefit Considerations section to reflect the most current information

Archived previous policy version 2025D0121O

Place of service 19 & 22Hospital outpatient locations addressed

6 monthsMax facility infusion duration

~100+Applicable provider-administered codes

42%Home infusion proportion (IDF survey)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Outpatient Hospital Facility Infusion

Outpatient hospital facility infusion — medical necessity criteria

Covered when AT LEAST ONE of the following is met and medical records are submitted:

Facility infusion criteria: Patient is medically unstable and at risk of requiring medical services and equipment available only in an outpatient hospital setting during administration (e.g., need for endotracheal tube, chest tube insertion equipment, cricothyroidotomy set, mechanical ventilator); examples include history of cardiopulmonary conditions that increase risk of severe adverse reactions or inability to tolerate fluid volume load despite using minimum infusion volume (e.g., unstable renal function).

Refer to chunks 4-5.

Physical/cognitive impairment: Treatment at an alternative site of care presents a health risk due to clinically significant physical or cognitive impairment.

Refer to chunk 5.

Severe vascular access issues: Severe patent vascular access issues for intravenous infusions requiring specialized equipment only available in an outpatient hospital setting (e.g., ultrasound guidance) and member is not a viable candidate for long-term vascular access devices (PICC line, port-a-cath).

Refer to chunk 5.

Prior severe adverse events: Previous episode(s) of severe or potentially life‑threatening adverse events (e.g., anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure), excluding the first or second infusion, that were unresponsive to standard interventions (acetaminophen, steroids, diphenhydramine, fluids, infusion rate reduction, or other pre-medications), increasing risk at alternative sites of care.

Refer to chunk 5.

Initial or re-initiation infusion: Initial infusion or re-initiation of previous therapy after more than 6 months (excludes drugs dosed at intervals ≥6 months) to justify short-duration hospital outpatient infusion (e.g., ~4 weeks).

Refer to chunk 5.

IVIG/SCIG specific: For IVIG or SCIG only: individual has immunoglobulin A (IgA) deficiency with anti-IgA antibodies.

Refer to chunk 5.

Home deemed unsuitable: All of the following: homecare/home infusion provider has deemed the individual or home environment unsuitable for home infusion; the prescriber is unable to administer in the office setting; and no ambulatory infusion suite options are available for the member.

Refer to chunk 5.

Site of Care — Appropriateness

Site of care options may be appropriate when patient meets clinical criteria and member benefits permit home or outpatient infusion:

General suitability for site of care: Select site of care based on patient clinical characteristics, prior infusion tolerance, and safety considerations: patients who have tolerated prior infusions without serious adverse events or who are clinically assessed appropriate for lower level supervision may be considered for home or office-based infusion; initial infusions and changes in product should occur in a facility equipped to manage severe acute medical complications.

Based on AAAAI guidance (chunk 31) and facility requirements (chunk 5).

ERT Homecare Prerequisites

Home infusion for enzyme replacement therapies may be allowed when ALL of the following are met:

ERT homecare prerequisites: Patient has received enzyme replacement therapy (ERT) in hospital for 3–6 months; any prior infusion‑related reactions (IRRs) are controlled with premedication; patient has had no IRR in the prior 2–8 weeks before homecare approval; premedication will be given for home infusions; and significant respiratory disease (percent predicted FVC ≤ 40% or evidence of serious obstructive airway disease) excludes homecare.

Derived from Hunter Syndrome European Expert Council recommendations (chunk 32).

If the member does not meet the medical necessity criteria for outpatient hospital facility infusion, alternative sites of care — including non-hospital outpatient infusion, physician office, ambulatory infusion suites, or home infusion services — are appropriate and should be used when clinically suitable. Documentation submitted with authorization requests should demonstrate why hospital outpatient facility-level care is required; absent that justification, providers should consider the lower-acuity site of care options listed above.

Patients with a history of prior serious infusion reactions (for example, anaphylaxis, seizure, myocardial infarction, or renal failure), individuals who are IGIV-naïve, or those who continue to experience moderate or serious infusion-related adverse events generally require higher levels of supervision and may need hospital outpatient or inpatient administration. Per AAAAI guidance, initial infusions and product changes should occur under physician supervision in a facility equipped to manage severe acute medical complications.

Services for which the provider does not submit medical record documentation demonstrating that the member meets the clinical criteria for hospital outpatient facility infusion, or that are inconsistent with the member-specific benefit plan document, may be considered not medically necessary or not covered. Providers must supply the clinical information requested to support a determination of medical necessity.

Listing of a procedure or diagnosis code in this policy is for reference only and does not by itself establish coverage. Benefit coverage and any determination of medical necessity depend on the member-specific Certificate of Coverage or Summary Plan Document and applicable laws or mandates; providers should confirm benefits and authorization requirements for the individual member before delivering services.

Initial and Re-initiation Infusion Requirements

Initial or re-initiation infusions

Initial infusion or re-initiation requirement

Initial/re-initiation: Initial infusion or re-initiation of therapy after >6 months (excludes drugs dosed at intervals ≥6 months) may require short‑duration hospital outpatient facility administration (example: up to ~4 weeks) to monitor for infusion‑related reactions.

Refer to chunk 5.

Initial Infusion Requirements

Initial infusions guidance

Initial infusion setting: All initial infusions of immune globulin (IGIV) should be administered under physician supervision in a facility equipped to manage severe acute medical complications; changes in IGIV products should also be provided under such supervision.

Per AAAAI guidelines (chunk 31).

Site-of-Care Considerations

Prior Authorization

Prior Authorization and Benefit Verification

Outpatient hospital facility infusion (Place of Service 19 or 22) requires prior authorization when the hospital outpatient site is requested for administration of specialty medications or IVIG/SCIG. Prior authorization determinations depend on the member's specific benefit plan and any applicable federal or state mandates. The member-specific benefit plan document governs in the event of a conflict.

Affected place of service codes: 19 (Off Campus–Outpatient Hospital) and 22 (On Campus–Outpatient Hospital).
Prior authorization requirement is subject to the member's plan terms; check benefit verification before scheduling.
UnitedHealthcare may reference third-party clinical tools (e.g., InterQual®) and member plan documents when making site-of-care determinations.

Documentation Required

Documentation Requirements and Denial Risk

Submission of adequate clinical documentation is required to support medical necessity for outpatient hospital facility–based infusion. Insufficient or missing documentation may result in denial or delay of authorization.

Applicable Codes and Coding Notes

Immune globulin codesHCPCS

90283	Immune globulin (IgIV), human, for intravenous use.
90284	Immune globulin (SCIg), human, for use in subcutaneous infusions, 100 mg, each

Selected HCPCS / unclassified drug codes listedHCPCS

C9399	Unclassified drugs or biologicals.
J0129	Injection, abatacept, 10 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered).
J0180	Injection, agalsidase beta, 1 mg.
J0217	Injection, velmanase alfa-tycv, 1 mg.
J0218	Injection, olipudase alfa-rpcp, 1 mg.
J0219	Injection, avalglucosidase alfa-ngpt, 4 mg.
J0221	Injection, alglucosidase alfa, (Lumizyme), 10 mg.
J0222	Injection, patisiran, 0.1 mg.
J0223	Injection, givosiran, 0.5 mg.
J0224	Injection, lumasiran, 0.5 mg.

1–10 of 18

1/2

Immunoglobulin procedure codesCPTCovered

90283	Immune globulin (IgIV), human, for intravenous use.
90284	Immune globulin (SCIg), human, for use in subcutaneous infusions, 100 mg, each

Applicable J- and Q-codes (provider-administered drugs)HCPCS

C9399	Unclassified drugs or biologicals.
J0129	Injection, abatacept, 10 mg (Medicare-specific note)
J0180	Injection, agalsidase beta, 1 mg.
J0217	Injection, velmanase alfa-tycv, 1 mg.
J0218	Injection, olipudase alfa-rpcp, 1 mg.
J0219	Injection, avalglucosidase alfa-ngpt, 4 mg.
J0221	Injection, alglucosidase alfa, (Lumizyme), 10 mg.
J0222	Injection, patisiran, 0.1 mg.
J0223	Injection, givosiran, 0.5 mg.
J0224	Injection, lumasiran, 0.5 mg.

1–10 of 99

1/10

Applicable HCPCS codes (updated)HCPCS

Q9998

Description revised in this policy per revision notes

Maximum ongoing facility-based infusion duration

Maximum ongoing facility-based infusion durationOngoing outpatient hospital facility-based infusion duration will be no more than 6 months to allow reassessment of suitability for alternative sites of care.

Reassessment intentTime-limited approval (6 months) is intended to permit evaluation for transition to lower-acuity site of care (office, ambulatory infusion suite, or home).

Applies toMedications requiring health care provider administration when outpatient hospital facility infusion criteria are met.

Required hospital ERT exposure before home care

Required hospital ERT exposure before home carePatient must have received enzyme replacement therapy (ERT) in hospital for 3–6 months before homecare is considered.

Provider Requirements and Actions

Prior Authorization

Outpatient hospital infusion — prior authorization & records

Prior authorization is required to request outpatient hospital facility infusion; submit medical records demonstrating that the outpatient hospital setting is medically necessary and reference the appropriate place of service code(s).

Include clinical documentation supporting at least one medical necessity criterion
Use POS 19 or 22 on claims for hospital outpatient facility infusion

Prior Authorization

Confirm benefits and obtain prior authorization

Obtain prior authorization when the member's plan provides medical necessity benefits for the requested medication; providers must confirm coverage and obtain authorization per the member‑specific benefits before scheduling facility infusion.

Confirm member has medical necessity coverage in Certificate of Coverage or Summary Plan Document
Request authorization per member-specific benefit rules

Background and Context

This policy defines when specialty medications and immune globulin therapies require administration in a hospital outpatient facility (place of service 19 or 22) rather than alternative sites of care. It outlines clinical criteria that justify facility-level infusion — for example, patients who are medically unstable, have prior severe infusion reactions, have severe vascular access problems, require initial or re-initiation infusions, or have specific IgG-related contraindications — and it references professional guidance (AAAAI) and specialty recommendations (Hunter Syndrome European Expert Council) supporting site-of-care decisions. When criteria are met, providers must submit medical records documenting the clinical rationale for outpatient hospital facility infusion.

Billing Rule

Infliximab — reference and biosimilar HCPCS codes included

The policy lists the reference infliximab HCPCS code J1745 alongside biosimilar HCPCS codes (Q5103, Q5104, Q5121); both reference and biosimilar codes are included for infliximab administration.

Reference code: J1745 (infliximab)
Biosimilar codes: Q5103, Q5104, Q5121

Definitions

Immune Globulin

Immune Globulin definitionImmune Globulin refers to therapeutic IgG (Immunoglobulin G) products addressed by this policy, including IVIG and SCIG.

Alternate namesAlso referred to as IG, immunoglobulin, gamma globulin; by route as IVIG/IGIV (intravenous) or SCIG/IGSC (subcutaneous).

ScopePolicy references pertain specifically to IgG products used therapeutically for replacement or immune modulation.

Site of Care

Site of Care definitionChoice of physical location for infusion administration: hospital inpatient, hospital outpatient, physician office, ambulatory infusion suite, or home-based setting.

Selection factorsSite selection should be based on patient clinical characteristics, prior infusion tolerance, and safety considerations.

Biosimilar Coding Notes

Billing Rule

J1745 and infliximab biosimilars are listed

This policy includes both the reference infliximab HCPCS code J1745 and the listed infliximab biosimilar HCPCS codes (Q5103, Q5104, Q5121) for documentation of infliximab administration.

J1745 and Q5103/Q5104/Q5121 are presented together in the applicable codes list

Policy Revision History

07/01/2025operational updateLatest

Updated list of applicable HCPCS codes to reflect quarterly edits and revised description for Q9998; Benefit Considerations section was updated.

Policy Summary

PayerUnitedHealthcare

PolicyProvider Administered Drugs - Site of Care

Policy CodePolicy 2025D0121P

Change TypeOperational updates to coding and supporting content (non-material)

Effective Date07/01/2025

Next Review DateN/A

Key ActionSubmit medical records and obtain prior authorization when requesting outpatient hospital facility infusion (place of service 19 or 22) to document medical necessity.

SourceLink

On This Page

Required documentation includes medical records that demonstrate why alternate Sites of Care are unsafe or unsuitable (see criteria: severe vascular access issues, prior severe infusion reactions, unsuitable home environment, initial/reinitiation infusions, IgA deficiency with anti-IgA antibodies for IG therapies).
If more than one approval criterion applies, the longest applicable approval period will be used; ongoing hospital outpatient approvals are limited to a maximum of 6 months for reassessment.
Provider must document attempts to arrange alternative sites (home infusion, ambulatory infusion suite, physician office) when relevant.

Note

Code Listing and Coverage Disclaimer

Listing a code in this policy does not guarantee coverage or payment. Coverage and payment depend on the member's benefit plan, documented medical necessity, and correct coding/billing.

Providers must verify coding and benefits prior to service and submit claims using appropriate place-of-service and facility codes.
Coding guidance in this policy is informational; it does not replace payer-specific billing instructions.

Billing Rule

Required Provider Actions

Follow these provider actions before delivering outpatient hospital facility infusion services to reduce risk of non-payment:

1) Complete benefit verification for the member and confirm prior authorization requirements based on the member plan.
2) Obtain and submit required medical records documenting the specific criterion(ia) that justify outpatient hospital administration.
3) Ensure drug-specific requirements (e.g., initial infusions, product changes, IG-specific IgA testing) are documented when applicable.
4) Confirm coding (POS, CPT, HCPCS, NDC where applicable) matches the site of care and billed service; correct coding does not alone assure coverage.

Premedication controlIf the patient previously had infusion-related reactions (IRRs), those reactions must be controlled with premedication prior to homecare.

DocumentationClinical records should document the hospital ERT period (3–6 months) and stability prior to approving home infusion for ERT.

Recent infusion reaction-free interval before homecare approval

Recent infusion reaction–free intervalNo infusion-related reaction (IRR) in the prior 2–8 weeks is required before homecare approval.

IRR controlAny prior IRRs must be controlled with premedication and premedication must be given for home infusions.

Source guidanceRequirement derived from Hunter Syndrome European Expert Council recommendations for safe home ERT transition.

Respiratory function cutoff

Respiratory function cutoffSignificant respiratory disease defined as %FVC 40% or less (or evidence of serious obstructive airway disease) — homecare may not be suitable.

Clinical implicationPatients meeting this cutoff should generally remain in hospital-based infusion settings for safety.

AssessmentDocument pulmonary function testing or clinical evidence of obstructive disease when considering site-of-care decisions for ERT homecare.

Note

Prior authorization depends on member's plan

Prior authorization requirements vary by member plan; this policy is guidance to help interpret benefit plans but authorization depends on the member's specific plan and applicable mandates.

Check member-specific plan for authorization applicability and any plan‑level limitations

Step Therapy

Refer to drug-specific Medical Benefit Drug Policy

Follow the applicable Medical Benefit Drug Policy for drug‑specific utilization management requirements (for example, step therapy or other prior treatment requirements).

Refer to the drug's Medical Benefit Drug Policy for required clinical information and utilization rules

Note

Drug‑formulation application note (Spevigo)

The policy explicitly applies Spevigo (spesolimab‑sbzo) only to the prefilled syringe for subcutaneous use; apply product‑specific site‑of‑care considerations accordingly.

Check formulation-specific notes in policy (e.g., Spevigo prefilled syringe)

Documentation Required

Medical record and HCPCS documentation required

Submit medical records documenting that outpatient hospital facility‑based administration is medically necessary and include the required clinical information per the applicable Medical Benefit Drug Policy; include the HCPCS code(s) for the drug being administered.

Provide clinical notes showing which medical necessity criterion is met
Include HCPCS code(s) and any drug‑specific documentation requested by the Medical Benefit Drug Policy

Billing Rule

Reference codes and verify member benefits

Reference the applicable procedure and diagnosis codes listed in the policy and confirm the member's Certificate of Coverage or Summary Plan Document shows medical necessity for the requested clinical use before authorizing facility infusion.

Use codes listed in the policy for claim/documentation purposes
Verify plan documents for coverage of the clinical indication

Documentation Required

Check member plan and applicable mandates

When deciding coverage, reference the member‑specific benefit plan document and check any applicable federal or state mandates to determine whether hospital outpatient infusion coverage applies.

Member-specific plan governs in case of conflict with this policy

Denial Risk

Insufficient documentation may lead to denial

Failure to provide documentation that clinical criteria are met or that hospital outpatient administration is medically necessary may result in denial of the request.

Ensure clinical records explicitly demonstrate which medical necessity criterion supports facility infusion

Billing Rule

Code listing does not guarantee coverage

Listing a code in this policy is for reference only and does not imply the service described by the code is covered or reimbursable; benefit coverage is determined by the member‑specific benefit plan and applicable laws.

Do not assume coverage solely because a HCPCS/CPT/J‑code appears in this policy

Note

Member-specific plan governs coverage

In case of any conflict between this policy and the member‑specific benefit plan document, the member‑specific plan governs; verify and follow that plan's terms when making coverage decisions.

Member-specific plan controls over standard policy in event of conflict

Place of service codesHospital outpatient place-of-service examples referenced elsewhere in the policy include CMS/AMA codes 19 (Off Campus-Outpatient Hospital) and 22 (On Campus-Outpatient Hospital).

IgG replacement therapy (IVIG/SCIG)

IgG replacement therapy descriptionImmunoglobulin (IgG) replacement therapy administers IgG intravenously (IVIG) or subcutaneously (SCIG) to patients with low IgG levels or function to reduce infections.

Dosing frequencyIVIG is commonly given monthly; SCIG may be administered weekly or biweekly depending on regimen.

ConsiderationsBoth IV and SC routes are effective; choice of route and site of care should be discussed with an allergist/immunologist and consider tolerability and risk of side effects (e.g., allergic reactions, headaches).